Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects

MarketWatch· Jaimy Lee· Sep 30, 2026 · 6:45 PM

The pharma giant is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes.

This is a summary. Read the complete story at MarketWatch below.

Read full article at MarketWatch

Billionaires like Ken Griffin are doling out tons of money to prove that a college degree still matters

Despite questions swirling around colleges and universities, Griffin’s $3 billion donation to Carnegie Mellon University is one of many from billionaires to colleges this year

MarketWatch

marketsabout 2 hours ago

After I sold TOMS Shoes for $400 million I was misdiagnosed with bipolar disorder — and it almost cost me everything

Most people land in a psychiatrist’s office because something happened: a loss, a breakup, the end of a career.

MarketWatch

marketsabout 2 hours ago

This chart shows that buying and holding stocks beats ‘sell in May and go away’ and other gimmicks

Followers of ‘sell in May and go away’ have lost out on a stock rally

MarketWatch

Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects

Related Stories

Billionaires like Ken Griffin are doling out tons of money to prove that a college degree still matters

After I sold TOMS Shoes for $400 million I was misdiagnosed with bipolar disorder — and it almost cost me everything

This chart shows that buying and holding stocks beats ‘sell in May and go away’ and other gimmicks